At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, discusses the ongoing phase 3 ARAMIS trial, which is evaluating the efficacy and safety of the novel androgen receptor inhibitor, ODM-201, in men with high-risk non-metastatic castration-resistant prostate cancer.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews